

主管：  
湖南省卫生健康委员会

主办：  
湖南省肿瘤医院

学术顾问：  
韩锐 霍仕文 马军  
梅建明 孙燕(院士)  
王忠民 胥彬 杨汉煜  
甄永苏(院士) 周宏灏(院士)

编委会主任：  
肖亚洲

名誉主编：  
任华益

主编：  
王静

副主编：  
董晓荣 廖前进 刘昭前  
欧阳取长 向阳 杨农  
杨小平 张会来 周辉

编辑部主任：  
廖前进

编辑：  
董珊珊 刘颖  
李征 于静

责任编辑：  
王娟

出版：  
《肿瘤药学》编辑部

国内发行：  
湖南省报刊发行局  
邮发代号：42-391

国外发行：  
中国国际图书贸易集团有限公司  
(北京399信箱，100048)  
代号：BM2809

## 目录

### 淋巴瘤研究新进展

复发/难治性套细胞淋巴瘤治疗进展 ..... 王晓晖, 费越, 王先火, 等	1
CAR-T细胞治疗淋巴瘤的进展 ..... 廖丹颖, 梅恒	9
外周T细胞淋巴瘤和结外NK/T细胞淋巴瘤研究进展 ..... 李静, 李志铭	16
弥漫大B细胞淋巴瘤治疗的研究进展 ..... 唐豪, 周明	22
奥布替尼联合利妥昔单抗及大剂量甲氨蝶呤治疗初治原发中枢神经系统淋巴瘤的疗效分析 ..... 闻淑娟, 朱琳, 吴梅, 等	30
奥妥珠单抗联合化疗治疗多线化疗后进展且塞利尼索无效的TP53突变Burkitt淋巴瘤 ..... 董丽丽, 黄赛, 赵志艺, 等	36
伊布替尼治疗慢性淋巴细胞白血病引起急性肾损伤不良反应1例 ..... 任志宏, 唐洋, 侯洁, 等	40
<b>综述</b>	
腔面型乳腺癌内分泌治疗耐药的研究进展 ..... 欧阳慧婷, 童璐, 易嘉宁, 等	45
<b>基础研究</b>	
新型双胍衍生物1-正戊基-5-(4-三氟甲氧基苯基)双胍联合奥希替尼抑制膀胱癌细胞增殖 ..... 彭妍, 周晓辰, 谢乐静, 等	53
基于气相色谱-质谱研究肝喜片处方中挥发性成分 ..... 陈玲珑, 陆艳艳, 彭艳梅	59
<b>临床研究</b>	
肝动脉灌注化疗(HAIC)在不可切除结直肠癌肝转移多线治疗耐药后的疗效分析 ..... 李国文, 黄满平, 黄斌, 等	65
基于真实世界的研究——646例肿瘤患者使用免疫检查点抑制剂相关不良反应的临床特征 ..... 叶淑芳, 刘苗兰, 仇晓霞	72
盐酸吗啡片动态滴定方法在肿瘤晚期患儿中的临床研究 ..... 封在李, 卢家强, 郭宏, 等	80

中国标准连续出版物号:

ISSN 2095-1264  
CN 43-1507/R

商标注册证号:

6125707

印刷:

长沙芙蓉印务广告有限公司

邮购:

《肿瘤药学》编辑部(长沙市岳麓区咸嘉湖路582号湖南省肿瘤医院,邮编:410013)

(本刊发行部全年办理补订手续)

电话:

0731-89762609

网址:

<http://www.zgzlyx.com>

中国知网优先数字出版网址:

<http://www.cnki.net>

邮箱:

[zgzlyx2011@163.com](mailto:zgzlyx2011@163.com)

微信服务号:

肿瘤药学杂志

定价:

每本30元,全年180元

出版日期:

2024年2月28日

期刊基本参数:

CN 43-1507/R\*2011\*B\*A4\*132\*  
ZH\*P\*¥30.00\*23\*2024-2

肺癌消积方联合吉非替尼治疗痰瘀互结型晚期非小细胞肺癌的临床疗效

..... 陈晶晶,王振强,张庆江,等 87

#### 循证医学

帕博利珠单抗治疗早期三阴性乳腺癌患者的安全性系统评价

..... 侯斯琦,张勇,张春霞 93

#### 药学服务

1例胰腺癌伴重度肾功能不全血液透析患者的药学监护

..... 王春晖,石培琪,梅清华,等 100

注射用多西他赛胶束无菌检查方法验证

..... 张国林,景荣先,邢以文 104

#### 肿瘤护理

基于跨理论模型的健康教育策略对乳腺癌患者内分泌治疗依从性的影响研究

..... 贺晓华,谌永毅,龚有文,等 108

等差递增肠内营养对肝门部胆管癌患者营养状况及喂养耐受性的影响

..... 张武爱,王展福 116

#### 病例报道

奥希替尼新辅助治疗ⅢA期EGFR突变肺腺癌后手术1例报道

..... 钟元,王卫谦 121

PD-1抑制剂引起的严重肝损伤及肝损伤后再挑战的病例系列报道

..... 钟宇科,刘文新,谢聪 126

本刊版权归《肿瘤药学》编辑部所有,如有印刷质量问题请向编辑部申请更换。

**Administrative Office:**

Health Commission of Hunan Province

**Sponsored by:**

Hunan Cancer Hospital

**Academic Advisor:**

HAN Rui, HUO Shiwen, MA Jun,  
MEI Jianming, SUN Yan,  
WANG Zhongmin, XU Bin, YANG Hanyu,  
ZHEN Yongsu, ZHOU Honghao

**Chief of Editorial Board:**

XIAO Yazhou

**Honorary Editor-in-Chief:**

REN Huayi

**Editor-in-Chief:**

WANG Jing

**Deputy Editor-in-Chief:**

DONG Xiaorong, LIAO Qianjin,  
LIU Zhaoqian, OUYANG Quchang,  
XIANG Yang, YANG Nong,  
YANG Xiaoping, ZHANG Huilai,  
ZHOU Hui

**Director of Editorial Department:**

LIAO Qianjin

**Editor:**

DONG Shanshan, LIU Ying,  
LI Zheng, YU Jing

**Editor in Charge:**

WANG Juan

**Publication:**

Editorial Department of *Anti-tumor  
Pharmacy*

**Domestic Distributor:**

Hunan Bureau for Distribution of  
Newspaper and Periodicals  
Code No. 42-391

**Overseas Distributor:**

China International Book Trading  
Corporation (P.O. Box 399, Beijing,  
100048, China)  
Code No. BM2809

## CONTENTS

### New Progress in Lymphoma Research

- Advances in the treatment of relapsed/refractory mantle cell lymphoma  
..... WANG Xiaohui, FEI Yue, WANG Xianhuo, et al. 1
- Advances in CAR-T cell therapy for lymphoma  
..... LIAO Danying, MEI Heng 9
- Research progress of peripheral T-cell lymphoma and extranodal NK/T-cell lymphoma  
..... LI Jing, LI Zhiming 16
- Progress in the treatment of diffuse large B-cell lymphoma  
..... TANG Hao, ZHOU Ming 22
- Orelabrutinib, rituximab and high-dose methotrexate for newly diagnosed primary  
central nervous system lymphoma: a retrospective analysis on efficacy and safety  
..... WEN Shujuan, ZHU Lin, WU Mei, et al. 30
- Obinutuzumab in combination with chemotherapy for TP53-mutated Burkitt lymphoma  
that progressed after multi-line chemotherapy and was selinexor-ineffective  
..... DONG Lili, HUANG Sai, ZHAO Zhiyi, et al. 36
- A case of acute kidney injury adverse reaction caused by ibrutinib in the treatment of  
chronic lymphocytic leukemia  
..... REN Zhihong, TANG Yang, HOU Jie, et al. 40

### Review

- Research progress on endocrine therapy resistance in luminal breast cancer  
..... OUYANG Huiting, TONG Lu, YI Jianing, et al. 45

### Basic Research

- A novel guanidine derivative 1-n-pentyl-5-(4-trifluoromethoxyphenyl) biguanide  
combined with osimertinib inhibited the proliferation of bladder cancer cells  
..... PENG Yan, ZHOU Xiaochen, XIE Lejing, et al. 53
- Study on the volatile components in Ganxi tablets based on GC-MS  
..... CHEN Linglong, LU Yanyan, PENG Yanmei 59

### Clinical Research

- Analysis of the efficacy of hepatic arterial infusion chemotherapy (HAIC) in the  
treatment of unresectable colorectal cancer liver metastases after drug resistance to  
multi-line treatment  
..... LI Guowen, HUANG Manping, HUANG Bin, et al. 65
- A real world research: the clinical characteristics of immune-related adverse events  
in 646 cases  
..... YE Shufang, LIU Miaolan, QIU Xiaoxia 72
- Clinical study of dynamic titration of morphine hydrochloride tablets for children with  
advanced tumors  
..... FENG Zaili, LU Jiaqiang, GUO Hong, et al. 80
- Clinical efficacy of Feiliu Xiaoji formula combined with gefitinib in treating advanced  
non-small cell lung cancer of phlegm and blood stasis type  
..... CHEN Jingjing, WANG Zhenqiang, ZHANG Qingjiang, et al. 87

**China Standard Serial Numbering:**

ISSN 2095-1264  
CN 43-1507/R

**Trademark Registration:**

6125707

**Printing:**

Changsha Fuyin Printing and Advertising Co., Ltd.

**Post Address:**

Editorial Department of *Anti-tumor Pharmacy* (No.582 Xianjiahu Road, Changsha, Hunan, China, 410013)

**Tel:** 0731-89762609

**Website:** <http://www.zgzlyx.com>

**Online First:** <http://www.cnki.net>

**E-mail:** [zgzlyx2011@163.com](mailto:zgzlyx2011@163.com)

**WeChat Service Account:**

AntiTumorPharmacy

**Price:** ¥30/Issue, ¥180/Year

**Publishing Date:**

Feb. 28, 2024

**Basic Information of the Journal:**

CN 43-1507/R\*2011\*B\*A4\*132\* ZH\*P\*  
¥30.00\*21\*2024-2

**Evidence-Based Medicine**

The safety of pembrolizumab in the treatment of early triple-negative breast cancer patients: a systematic review  
..... HOU Siqi, ZHANG Yong, ZHANG Chunxia 93

**Pharmacy Service**

Pharmaceutical care for a pancreatic cancer patient with severe renal insufficiency undergoing hemodialysis  
..... WANG Chunhui, SHI Peiqi, MEI Qinghua, et al. 100  
Sterility test validation of docetaxel micelles for injection  
..... ZHANG Guolin, JING Rongxian, XING Yiwu 104

**Nursing**

Effects of a trans-theoretical model-based health education strategy on the adherence of breast cancer patients undergoing adjuvant endocrine therapy  
..... HE Xiaohua, CHEN Yongyi, GONG Youwen, et al. 108  
Effect of iso-incremental enteral nutrition infusion on the nutritional status and feeding tolerance of patients with hilar cholangiocarcinoma  
..... ZHANG Wu'ai, WANG Zhanfu 116

**Case Report**

Osimertinib neoadjuvant therapy followed by thoracoscopic lobectomy for stage III A EGFR-mutated lung adenocarcinoma: a case report  
..... ZHONG Yuan, WANG Weiqian 121  
Clinical characteristics of severe hepatotoxicity induced by PD-1 inhibitors and rechallenge after hepatotoxicity: a case series report  
..... ZHONG Yuke, LIU Wenxin, XIE Cong 126

• 特别声明 •

本刊作者文责自负,稿件一经采用,该文的复制权、发行权、信息网络传播权、汇编权等相关权利视为自动转让给本刊。本刊有权将上述权利转授给收录本刊的数据库,如作者不同意文章被转录,请来稿时注明,本刊将做适当处理。